InspireMD (NSPR) CCO executes automatic sell-to-cover stock sales

Rhea-AI Filing Summary

InspireMD Chief Commercial Officer Shane Thomas Gleason reported a series of automatic stock sales to cover taxes on vested restricted stock. Between mid-January and early February 2026, he sold multiple small blocks of InspireMD common stock under a pre-established sell-to-cover instruction.

The filing explains that these transactions were required to satisfy tax withholding obligations tied to restricted stock vesting and were executed pursuant to an automatic sales instruction letter adopted on November 25, 2024, rather than being discretionary trades. After the most recent sale, Gleason beneficially owned 1,139,177 shares of InspireMD common stock directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gleason Shane Thomas

(Last) (First) (Middle)

C/O INSPIREMD, INC.

6303 WATERFORD DISTRICT DRIVE, SUITE 215

(Street)

MIAMI FL 33126

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
InspireMD, Inc. [ NSPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/15/2026		S		2,909(1)	D	$1.579	1,197,462	D
Common Stock	01/16/2026		S		2,250(1)	D	$1.612	1,195,212	D
Common Stock	01/20/2026		S		2,955(1)	D	$1.594	1,192,257	D
Common Stock	01/21/2026		S		17,593(1)	D	$1.623	1,174,664	D
Common Stock	01/22/2026		S		8,411(1)	D	$1.574	1,166,253	D
Common Stock	01/27/2026		S		4,781(1)	D	$1.664	1,161,472	D
Common Stock	01/28/2026		S		12,395(1)	D	$1.651	1,149,077	D
Common Stock	01/29/2026		S		5,000(1)	D	$1.65	1,144,077	D
Common Stock	01/30/2026		S		2,900(1)	D	$1.631	1,141,177	D
Common Stock	02/02/2026		S		2,000(1)	D	$1.604	1,139,177	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 represent shares of common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock grants pursuant to an automatic sales instruction letter adopted by the Reporting Person on November 25, 2024 effecting the sell-to-cover election. These sales do not represent discretionary trades by the Reporting Person.

Remarks:

Exhibit 24.1: Power of Attorney

	/s/ Michael Lawless, Attorney-in-Fact for Shane Gleason	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did InspireMD (NSPR) disclose in this Form 4 filing?

InspireMD reported automatic stock sales by its Chief Commercial Officer. Shane Thomas Gleason sold shares of common stock to cover tax withholding obligations from restricted stock vesting, under a pre-arranged sell-to-cover instruction, and retained over 1.13 million shares afterward.

How many InspireMD (NSPR) shares does the CCO hold after these sales?

After the reported transactions, the CCO beneficially owns 1,139,177 shares. This figure reflects his direct ownership of InspireMD common stock immediately following the final sale disclosed in the Form 4, according to the company’s Section 16 filing.

Why did the InspireMD (NSPR) CCO sell shares in January–February 2026?

The shares were sold to cover tax withholding obligations. The filing states that the sales resulted from an automatic sell-to-cover election tied to the vesting of restricted stock grants, rather than from discretionary trading decisions by the executive.

Were the InspireMD (NSPR) insider stock sales discretionary trades?

No, the filing states these were not discretionary trades. The sales followed an automatic sales instruction letter adopted on November 25, 2024, specifically to sell shares needed to satisfy tax withholding on vested restricted stock grants.

What role does the reporting person hold at InspireMD (NSPR)?

The reporting person is InspireMD’s Chief Commercial Officer. Shane Thomas Gleason is identified in the filing as an officer of the company, with his position listed as Chief Commercial Officer and the transactions reported as his direct holdings.

Over what period did the InspireMD (NSPR) insider sales occur?

The reported sales occurred from January 15 to February 2, 2026. During this period, the Chief Commercial Officer executed multiple small sell-to-cover transactions in InspireMD common stock to meet tax obligations from restricted stock vesting.